Table 1.
Clinical features of patients, donors, and transplants.
| Variables | All patients (246) | Myeloid cohort (142) | Lymphoid cohort (104) |
|---|---|---|---|
| Median patient age (years) | 30 (9–60) | 33 (9–60) | 24 (13–56) |
| Median donor age (years) | 35 (11–59) | 32 (11–55) | 38 (13–59) |
| Median MNC cells (×10 E8/kg) | 15.34 (2.97–59.80) | 14.36 (2.97–59.80) | 15.61 (5.80–46.14) |
| Median CD34+ cells (×10 E6/kg) | 6.30 (0.27–34.37) | 6.06 (0.27–34.37) | 7.03 (1.77–22.87) |
| Median follow up time (years) | 3.0 (0.1–5.5) | 3.0 (0.2–5.5) | 2.9 (0.1–5.5) |
| Patient sex | |||
| Male Female |
136 (55.3) 110 (44.7) |
77 (54.2) 65 (45.8) |
59 (56.7) 45 (43.3) |
| Donor/Patient sex combination | |||
| Female/Male Other combinations |
44 (17.9) 202 (82.1) |
27 (19.0) 115 (81.0) |
17 (16.3) 87 (83.7) |
| ABO blood mismatch | |||
| Identical Mismatch |
131 (53.3) 115 (46.7) |
73 (51.4) 69 (48.6) |
58 (55.8) 46 (44.2) |
| Diagnosis | / | / | |
| AML MDS MPN ALL Lymphoma |
115 (46.7) 22 (8.9) 5 (2.0) 93 (37.8) 11 (4.5) |
||
| Disease status at HSCT | |||
| CR1 >CR1 |
181 (73.5) 65 (26.4) |
99 (69.7) 43 (30.3) |
82 (78.9) 22 (21.2) |
| Disease risk index | |||
| Low/Int risk High/Very high risk |
173 (70.3) 73 (29.7) |
93 (65.5) 49 (34.5) |
80 (76.9) 24 (23.1) |
| Conditioning regimen | |||
| MAC RIC |
233 (94.7) 13 (5.3) |
133 (93.7) 9 (6.3) |
100 (96.2) 4 (3.8) |
| ATG | |||
| ATG-F ATG-G |
205 (83.3) 41 (16.7) |
117 (82.4) 25 (17.6) |
88 (84.6) 16 (15.4) |
| HLA ligands of patients | |||
| A3/A11+
Bw4+ C1/C1 C1/C2 C2/C2 |
115 (46.7) 148 (60.2) 167 (67.9) 68 (27.6) 11 (4.5) |
66 (46.5) 90 (63.4) 95 (66.9) 42 (29.6) 5 (3.5) |
49 (47.1) 58 (55.8) 72 (69.2) 24 (23.1) 6 (5.8) |
| Receptor-ligand (R-L) model | |||
| R-L A3/A11 mismatch R-L Bw4 mismatch R-L C mismatch |
131 (53.3) 96 (39.0) 176 (71.5) |
76 (53.5) 49 (34.5) 98 (69.0) |
55 (52.9) 47 (45.2) 78 (75.0) |
| Donor KIR genotype | |||
| AA B/x BA BB |
143 (58.1) 103 (41.9) 76 (30.9) 27 (11.0) |
81 (57.0) 61 (43.0) 45 (31.7) 16 (11.3) |
62 (59.6) 42 (40.4) 31 (29.8) 11 (10.6) |
| Donor activating KIR gene | |||
| KIR2DS1+
KIR2DS2+ KIR2DS3+ KIR2DS4+ KIR2DS5+ KIR3DS1+ |
83 (33.7) 46 (18.7) 41 (16.7) 238 (96.7) 57 (23.2) 85 (34.6) |
49 (34.5) 27 (19.0) 24 (16.9) 135 (95.1) 36 (25.4) 51 (35.9) |
34 (32.7) 19 (18.3) 17 (16.3) 103 (99.0) 21 (20.2) 34 (32.7) |
| iKIR-HLA pairs variation | |||
| A3/A11 | |||
| Decreased (D) Unchanged (U) Increased (I) |
40 (16.2) 166 (67.5) 40 (16.2) |
22 (15.5) 98 (69.0) 23 (16.2) |
18 (17.3) 68 (65.4) 17 (16.3) |
| Bw4 | |||
| Decreased (D) Unchanged (U) Increased (I) |
26 (10.6) 189 (76.8) 31 (12.6) |
14 (9.9) 109 (76.8) 19 (13.4) |
12 (11.5) 80 (76.9) 12 (11.5) |
| C | |||
| Decreased (D) Unchanged (U) Increased (I) |
43 (17.5) 163 (66.3) 40 (16.3) |
20 (14.1) 98 (69.0) 24 (16.9) |
23 (22.1) 65 (58.7) 16 (15.4) |
| EBV viremia | 90 (36.6) | 41 (28.9) | 49 (47.1) |
| CMV viremia | 160 (65.0) | 93 (65.5) | 67 (64.4) |
| aGVHD | |||
| Grade 0 Grade I Grade II Grade III Grade IV |
92 (37.4) 71 (28.9) 55 (22.4) 12 (4.9) 16 (6.5) |
55 (38.7) 44 (31.0) 30 (21.1) 7 (4.9) 6 (4.2) |
37 (35.6) 27 (26.0) 25 (24.0) 5 (4.8) 10 (9.6) |
| cGVHD | |||
| Not included No Mild Moderate Severe |
7 (2.8) 139 (56.5) 58 (23.6) 26 (10.6) 16 (6.5) |
2 (1.4) 76 (53.5) 39 (27.5) 14 (9.9) 11 (7.7) |
5 (4.8) 63 (60.6) 19 (18.3) 12 (11.5) 5 (4.8) |
| relapse | 55 (22.4) | 28 (16.9) | 27 (26.0) |
| NRM | 14 (5.7) | 4 (2.8) | 10 (9.6) |
| OS | 185(75.2) | 115 (82.4) | 70 (67.3) |
| DFS | 177 (72.0) | 110 (80.3) | 67 (64.4) |
AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; ALL, acute lymphoblastic leukemia; MNC, mononuclear; CR1, first complete remission; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; ATG, Antithymocyte Globulin; EBV, Epstein-Barr virus; CMV, cytomegalovirus; aGVHD, acute graft versus host disease; cGVHD, chronic graft versus host disease; NRM, non-relapse mortality; OS, overall survival; DFS, disease-free survival.